These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 411251)

  • 1. [Use of the peroral TRH test in the diagnosis of acromegaly].
    Felt V; Nedvídková J
    Vnitr Lek; 1977 Sep; 23(9):865-7. PubMed ID: 411251
    [No Abstract]   [Full Text] [Related]  

  • 2. Growth hormone response to oral TRH as a diagnostic aid in acromegaly.
    Martínez-Campos A; Nieto L; Tovar E; Maisterrena J; García-Reyes JA; Valverde C
    Rev Invest Clin; 1978; 30(2):127-30. PubMed ID: 97744
    [No Abstract]   [Full Text] [Related]  

  • 3. [The use of thyreoliberin VUFB in the diagnosis of acromegaly (author's transl)].
    Felt V; Nedvídková J; Shameti H; Kasafírek E
    Cas Lek Cesk; 1979 Feb; 118(8):232-4. PubMed ID: 109212
    [No Abstract]   [Full Text] [Related]  

  • 4. [Determination of growth hormone response to thyreoliberin in the evaluation of lisuride therapy of acromegaly].
    Felt V; Nedvídková J
    Vnitr Lek; 1982 Aug; 28(8):756-61. PubMed ID: 6814061
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of thyroliberin (TRH), bromocriptine and cyproheptadine on somatotropin secretion in acromegaly.
    Pawlikowski M; Strejczek H; Owczarczyk I; Komorowski J
    Mater Med Pol; 1980; 12(1-2):70-3. PubMed ID: 6799708
    [No Abstract]   [Full Text] [Related]  

  • 6. Growth hormone and changes in the secretion of thyrotropic hormone after thyrotropin-releasing hormone (TRH): ineffectiveness of dopaminergic stimulation.
    Felt V; Nedvídková J
    Endokrinologie; 1982 Oct; 80(2):201-6. PubMed ID: 6819130
    [No Abstract]   [Full Text] [Related]  

  • 7. [Sulpiride and TRH loading tests in acromegaly].
    Zséli J; Földes J; Holló I; Kollin E; Horváth C; Gács G; Borvendég J
    Orv Hetil; 1980 Oct; 121(42):2569-72. PubMed ID: 6780963
    [No Abstract]   [Full Text] [Related]  

  • 8. Serum levels of thyrotropin, prolactin, growth hormone, triiodothyronine and thyroxine after oral administration of thyrotropin releasing hormone in hypothyroid and hyperthyroid patients.
    Nedvídková J; Felt V
    Endokrinologie; 1976; 68(2):175-82. PubMed ID: 827434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [GH and PRL after TRH and hpGRF(1-40) administration in 2 cases of acromegaly with hyperprolactinemia].
    Sampaolo G; Faloia E; Sarzani R; Bartolacci V; Schiavo P; Butini L; Morosini P
    Recenti Prog Med; 1987 Mar; 78(3):115-8. PubMed ID: 3110882
    [No Abstract]   [Full Text] [Related]  

  • 10. [Growth hormone liberation after TRH in patients with acromegaly].
    Morosini PP; Campanella N; Carletti P; Sturbini S; Testa I
    Boll Soc Ital Biol Sper; 1980 Jun; 56(12):1239-42. PubMed ID: 6779828
    [No Abstract]   [Full Text] [Related]  

  • 11. [Hormonal evaluation of 27 patients with acromegaly].
    Villabona C; Novials A; Soler J; Morató J; Gómez JM; Navarro MA
    Med Clin (Barc); 1985 Feb; 84(6):219-22. PubMed ID: 3920452
    [No Abstract]   [Full Text] [Related]  

  • 12. Growth hormone in the blood of patients after administration of synthetic thyrotropin releasing hormone.
    Nedvídková J; Felt VI
    Vnitr Lek; 1976 May; 22(5):453-6. PubMed ID: 820068
    [No Abstract]   [Full Text] [Related]  

  • 13. Long-term treatment of acromegaly with Sandostatin (SMS 201-995). Normalization of most anomalous growth hormone responses.
    Pieters GF; van Liessum PA; Smals AG; van Gennep JA; Benraad TJ; Kloppenborg PW
    Acta Endocrinol Suppl (Copenh); 1987; 286():9-18. PubMed ID: 2892339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth hormone (GH)-releasing activity of TRH and GH-lowering effect of dopaminergic drugs in acromegaly: homogeneity in the two responses.
    Liuzzi A; Chiodini PG; Botalla L; Silvestrini F; Müller EE
    J Clin Endocrinol Metab; 1974 Nov; 39(5):871-6. PubMed ID: 4214404
    [No Abstract]   [Full Text] [Related]  

  • 15. Paradoxic elevation in serum GH by hypothalamic releasing hormones predicts GH response to acute SMS 201-995 administration.
    Candrina R
    Recenti Prog Med; 1991 Jan; 82(1):13-6. PubMed ID: 1902962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Growth hormone secretion in relation to changes in thyrotropic hormone after thyroliberin in patients with acromegaly and dopaminergic stimulation (author's transl)].
    Felt V; Nedvídková J
    Cas Lek Cesk; 1982 Apr; 121(16):489-93. PubMed ID: 6807547
    [No Abstract]   [Full Text] [Related]  

  • 17. [Reevaluation of the I-dopa test in acromegaly: anatomo-clinical and prognostic correlations].
    De Marinis L; Mancini A; Zuppi P; Fiumara C; Iacona T; Conte G; Fabrizi ML; Valle D; Anile C; Maira G
    Minerva Chir; 1993 Nov; 48(21-22):1337-40. PubMed ID: 8152567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cure and quiescent period in acromegaly. Long-term results of surgery or radiotherapy].
    Barreiro N; Velasco F; Mora R; Larraza O; Fanghanel G; Hernández M; García-Reyes JA; Valverde C
    Rev Invest Clin; 1982; 34(4):321-6. PubMed ID: 6820540
    [No Abstract]   [Full Text] [Related]  

  • 19. [Progress in diagnosis of acromegaly].
    Shizume K
    Nihon Rinsho; 1979; 37(4):792-5. PubMed ID: 109650
    [No Abstract]   [Full Text] [Related]  

  • 20. [Peripheral thyroid function and TRH-TSH test in patients with acromegaly].
    Heberling HJ; Heilmann W; Ulrich FE; Schneyer U
    Z Gesamte Inn Med; 1981 Apr; 36(8):306-8. PubMed ID: 6792802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.